These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

436 related items for PubMed ID: 18562406

  • 1. Catatonia, neuroleptics and brain damage--a case report.
    Chandran M, El-Shazly M.
    J Psychopharmacol; 2009 Mar; 23(2):223-6. PubMed ID: 18562406
    [Abstract] [Full Text] [Related]

  • 2. Catatonia as a risk factor for the development of neuroleptic malignant syndrome: report of a case following treatment with clozapine.
    Paparrigopoulos T, Tzavellas E, Ferentinos P, Mourikis I, Liappas J.
    World J Biol Psychiatry; 2009 Mar; 10(1):70-3. PubMed ID: 19673089
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. [Differential diagnosis of malignant hyperthermia, febrile catatonia and neuroleptic malignant syndrome. A case comparison].
    Schröder J, Linge C, Wähner A.
    Fortschr Neurol Psychiatr; 1988 Mar; 56(3):97-101. PubMed ID: 2896144
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. [Catatonia and neuroleptic malignant syndrome: two disorders on a same spectrum? Three case reports].
    Luchini F, Lattanzi L, Bartolommei N, Cosentino L, Casamassima F, Litta A, Mauri M, Cassano GB.
    Riv Psichiatr; 2012 Mar; 47(2):178-85. PubMed ID: 22622253
    [Abstract] [Full Text] [Related]

  • 11. Neuroleptic malignant syndrome due to atypical neuroleptics: three episodes in one patient.
    Bottlender R, Jäger M, Hofschuster E, Dobmeier P, Möller HJ.
    Pharmacopsychiatry; 2002 May; 35(3):119-21. PubMed ID: 12107858
    [Abstract] [Full Text] [Related]

  • 12. Clinical risk factors for neuroleptic malignant syndrome.
    Berardi D, Dell'Atti M, Amore M, De Ronchi D, Ferrari G.
    Hum Psychopharmacol; 2002 Mar; 17(2):99-102. PubMed ID: 12404699
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Neuroleptic malignant syndrome and catatonia. A report of three cases.
    Raja M, Altavista MC, Cavallari S, Lubich L.
    Eur Arch Psychiatry Clin Neurosci; 1994 Mar; 243(6):299-303. PubMed ID: 7913834
    [Abstract] [Full Text] [Related]

  • 17. [Neuroleptic malignant syndrome under amisulpride in a patient during a second acute psychotic episode].
    Barrimi M, El Ghazouani F, Zaimi O, Oneib B.
    Presse Med; 2018 Feb; 47(2):172-174. PubMed ID: 29395559
    [No Abstract] [Full Text] [Related]

  • 18. Neuroleptic malignant syndrome and catatonia: one entity or two?
    Fink M.
    Biol Psychiatry; 1996 Jan 01; 39(1):1-4. PubMed ID: 8719118
    [No Abstract] [Full Text] [Related]

  • 19. Neuroleptic malignant syndrome without fever after addition of oxcarbazepine to long-term treatment with amisulpride.
    Angelopoulos P, Markopoulou M, Kyamidis K, Bobotas K.
    Gen Hosp Psychiatry; 2008 Jan 01; 30(5):482-4. PubMed ID: 18774435
    [Abstract] [Full Text] [Related]

  • 20. Catatonia in psychiatric classification.
    Van Den Eede F, Sabbe B.
    Am J Psychiatry; 2004 Dec 01; 161(12):2327-8; author reply 2328. PubMed ID: 15569914
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.